Intellia Therapeutics, Inc. (NTLA) Bundle
Understanding Intellia Therapeutics, Inc. (NTLA) Revenue Streams
Understanding Intellia Therapeutics, Inc. (NTLA) Revenue Streams
The primary revenue source for the company is collaboration revenue, which includes payments received from collaboration agreements with other companies.
Breakdown of Primary Revenue Sources
-
Collaboration Revenue:
- For the nine months ended September 30, 2024: $45.0 million
- For the nine months ended September 30, 2023: $38.2 million
- Other Revenue: Minimal revenue recognized from other collaborations, such as AvenCell, Kyverna, and ONK.
Year-over-Year Revenue Growth Rate
The collaboration revenue increased by $6.8 million, representing a growth rate of approximately 17.8% from 2023 to 2024.
Contribution of Different Business Segments to Overall Revenue
| Segment | Revenue (2024) | Revenue (2023) | Change ($) | Percentage Change (%) |
|---|---|---|---|---|
| Collaboration Revenue | $45,003,000 | $38,192,000 | $6,811,000 | 17.8% |
| Other Revenue Sources | Minimal | Minimal | - | - |
Analysis of Any Significant Changes in Revenue Streams
The increase in collaboration revenue was primarily driven by the recognition of $21.0 million of previously eliminated intra-entity profit under the AvenCell collaboration agreement. This was partially offset by a $12.4 million reduction in revenue related to the AvenCell license agreement.
During the nine months ended September 30, 2024, the company recognized approximately $6.4 million and $16.1 million in collaboration revenue during the three and nine months ended September 30, 2024, respectively. This compares to $5.5 million and $14.2 million for the same periods in 2023.
Summary of Financial Performance
The overall operating loss for the nine months ended September 30, 2024, was $397.8 million, compared to $375.4 million for the same period in 2023. This indicates an increase in operational costs, primarily in research and development expenses.
A Deep Dive into Intellia Therapeutics, Inc. (NTLA) Profitability
A Deep Dive into Intellia Therapeutics, Inc. Profitability
Gross Profit Margin: As of September 30, 2024, the gross profit margin was not applicable as the company did not generate product revenue.
Operating Profit Margin: For the nine months ended September 30, 2024, the operating loss was $397.8 million, leading to an operating profit margin of -884.5% (calculated as operating loss divided by total revenue).
Net Profit Margin: The net loss for the nine months ended September 30, 2024 was $390.1 million, resulting in a net profit margin of -866.7%.
Trends in Profitability Over Time
The following table summarizes the profitability metrics for the nine months ended September 30 for 2024 and 2023:
| Metric | 2024 | 2023 |
|---|---|---|
| Net Loss ($ million) | 390.1 | 349.0 |
| Operating Loss ($ million) | 397.8 | 375.4 |
| Collaboration Revenue ($ million) | 45.0 | 38.2 |
Comparison of Profitability Ratios with Industry Averages
As of September 30, 2024, the company’s net profit margin of -866.7% and operating profit margin of -884.5% are significantly lower than the industry average for biotechnology companies, which typically ranges from -20% to -40%.
Analysis of Operational Efficiency
Research and development expenses for the nine months ended September 30, 2024, were $349.4 million, compared to $326.1 million in the same period of 2023, reflecting a 7.0% increase. General and administrative expenses increased to $93.4 million from $87.5 million, a 6.8% increase.
The breakdown of operating expenses is as follows:
| Expense Type | 2024 ($ million) | 2023 ($ million) |
|---|---|---|
| Research and Development | 349.4 | 326.1 |
| General and Administrative | 93.4 | 87.5 |
| Total Operating Expenses | 442.8 | 413.6 |
As of September 30, 2024, the company reported an accumulated deficit of $2,048.5 million, indicating ongoing challenges in achieving operational efficiency and profitability.
Debt vs. Equity: How Intellia Therapeutics, Inc. (NTLA) Finances Its Growth
Debt vs. Equity: How Intellia Therapeutics, Inc. Finances Its Growth
As of September 30, 2024, Intellia Therapeutics, Inc. has total liabilities of $210.736 million and total stockholders’ equity of $962.615 million. This structure highlights the company's reliance on equity financing over debt.
Overview of the Company's Debt Levels
Intellia does not have long-term debt reported on its balance sheet, indicating a strategy focused on equity financing. Current liabilities as of September 30, 2024, include accounts payable of $14.329 million and accrued expenses of $14.336 million. This minimal short-term debt suggests a conservative approach to leveraging.
Debt-to-Equity Ratio and Comparison to Industry Standards
The debt-to-equity ratio is calculated by dividing total liabilities by total stockholders’ equity. For Intellia, this ratio stands at approximately 0.22 ($210.736 million / $962.615 million). This is significantly lower than the industry average for biotech companies, which typically ranges from 0.5 to 1.0, indicating a lower reliance on debt financing.
Recent Debt Issuances, Credit Ratings, or Refinancing Activity
Intellia has not issued any debt instruments as of the latest reporting period. The absence of long-term debt and the lack of recent refinancing activities suggest a strategy that prioritizes equity financing, particularly through at-the-market offerings.
How the Company Balances Between Debt Financing and Equity Funding
Intellia’s strategy to finance its operations has primarily involved equity funding. The company raised $176.9 million from at-the-market offerings during the nine months ended September 30, 2024. This reflects a significant reliance on equity to support ongoing research and development activities.
| Financial Metric | Amount (in millions) |
|---|---|
| Total Liabilities | $210.736 |
| Total Stockholders’ Equity | $962.615 |
| Debt-to-Equity Ratio | 0.22 |
| Net Proceeds from At-the-Market Offerings (2024) | $176.9 |
As of September 30, 2024, the company had $944.7 million in cash, cash equivalents, and marketable securities, which provides a solid financial cushion for its operations.
Assessing Intellia Therapeutics, Inc. (NTLA) Liquidity
Assessing Liquidity and Solvency
As of September 30, 2024, the company's liquidity position is supported by a robust balance of cash and cash equivalents totaling $120.5 million and marketable securities amounting to $537.6 million. This provides a total of $658.1 million in current assets available for operational needs.
Current and Quick Ratios
The current ratio, calculated as current assets divided by current liabilities, stands at:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $710.9 million | $105.7 million | 6.72 |
The quick ratio, which excludes inventory from current assets, is calculated using cash and cash equivalents, marketable securities, and accounts receivable:
| Quick Assets | Current Liabilities | Quick Ratio |
|---|---|---|
| $667.0 million | $105.7 million | 6.31 |
Analysis of Working Capital Trends
The working capital, defined as current assets minus current liabilities, is calculated as follows:
| Current Assets | Current Liabilities | Working Capital |
|---|---|---|
| $710.9 million | $105.7 million | $605.2 million |
Working capital has shown a significant increase compared to the previous year, indicating a strengthening liquidity position.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow statement reflects the following:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | ($263,685) | ($301,032) |
| Net Cash Used in Investing Activities | ($25,998) | ($77,286) |
| Net Cash Provided by Financing Activities | $183,430 | $23,839 |
The net cash used in operating activities decreased, indicating improved operational efficiency. The financing activities reflect a notable increase due to the successful execution of at-the-market offerings.
Potential Liquidity Concerns or Strengths
The company has raised a total of $2.76 billion since inception to support its operations. This includes proceeds from equity offerings and collaborations. However, the net loss for the nine months ended September 30, 2024, was ($390.1 million), contributing to an accumulated deficit of ($2.05 billion).
The liquidity position is further bolstered by the anticipated funding from collaboration agreements and the ability to generate cash through future equity offerings, although this could dilute existing shareholders. Total liabilities are reported at $210.7 million, with total stockholders' equity at $962.6 million as of September 30, 2024.
Is Intellia Therapeutics, Inc. (NTLA) Overvalued or Undervalued?
Valuation Analysis
In assessing the financial health of the company, various valuation metrics provide insight into whether the stock is overvalued or undervalued. Key ratios include Price-to-Earnings (P/E), Price-to-Book (P/B), and Enterprise Value-to-EBITDA (EV/EBITDA).
Price-to-Earnings (P/E) Ratio
As of September 30, 2024, the company's net loss was $390.1 million, resulting in a basic and diluted loss per share of $3.99 for the nine months ended September 30, 2024. Given the lack of earnings, the P/E ratio is not applicable.
Price-to-Book (P/B) Ratio
The book value per share can be calculated as follows:
- Total Stockholders’ Equity: $962.6 million
- Shares Outstanding: 101.8 million
- Book Value per Share: $9.45 (calculated as $962.6 million / 101.8 million)
Assuming a current stock price of $25.68 (average price from recent offerings), the P/B ratio is approximately 2.72 (calculated as $25.68 / $9.45).
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value can be calculated using the formula:
- Market Capitalization: $2.61 billion (using the stock price and shares outstanding)
- Total Debt: $210.7 million
- Cash and Cash Equivalents: $120.5 million
- Enterprise Value: $2.60 billion (Market Cap + Total Debt - Cash)
From the financial statements, the EBITDA is not provided directly, as the company has not reported positive earnings. Hence, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
Over the last 12 months, the stock price has experienced fluctuations. The stock opened at $20.00 and reached a high of $35.00 before settling around $25.68.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, resulting in a dividend yield of 0.0%.
Analyst Consensus on Stock Valuation
Analysts have a mixed consensus on the stock valuation. According to recent reports, the consensus rating is a Hold, with price targets ranging from $20.00 to $30.00.
| Metric | Value |
|---|---|
| Net Loss (9M 2024) | $390.1 million |
| Loss per Share | $3.99 |
| Book Value per Share | $9.45 |
| Current Stock Price | $25.68 |
| P/B Ratio | 2.72 |
| Market Capitalization | $2.61 billion |
| Total Debt | $210.7 million |
| Cash and Cash Equivalents | $120.5 million |
| Dividend Yield | 0.0% |
| Analyst Consensus | Hold |
Key Risks Facing Intellia Therapeutics, Inc. (NTLA)
Key Risks Facing Intellia Therapeutics, Inc.
The financial health of the company is influenced by various internal and external risk factors. An overview of these risks is crucial for investors.
Overview of Internal and External Risks
Competition within the biotechnology sector remains a significant concern. As of September 30, 2024, the company reported a net loss of $390.1 million, reflecting ongoing challenges in achieving profitability . The industry is characterized by rapid technological advancements and a high level of competition, which can impact market share and pricing strategies.
Regulatory changes also pose risks. The company must navigate complex regulatory environments to obtain necessary approvals for its products. As of September 30, 2024, the accumulated deficit stood at $2.048 billion, indicating the financial strain associated with regulatory compliance and development costs .
Operational Risks
Operational risks include challenges in managing research and development (R&D) expenditures, which totaled $349.4 million for the nine months ended September 30, 2024 . Furthermore, the company has not yet successfully commercialized any products, which creates uncertainty about future revenues.
Financial Risks
Financial risks are compounded by the need for substantial funding to support ongoing operations. The company has raised $2.758 billion since inception through various financing methods . As of September 30, 2024, cash, cash equivalents, and marketable securities totaled $944.7 million, but ongoing losses may necessitate additional financing .
Strategic Risks
Strategic risks include potential difficulties in executing collaborations and partnerships. The company has agreements that could yield milestone payments of up to $320 million but must maintain favorable relationships with partners to realize these opportunities .
Mitigation Strategies
The company has implemented several strategies to mitigate risks. It has expanded its at-the-market offering program to raise up to $750 million. Additionally, it has focused on reducing operational costs, evidenced by a $5.3 million decrease in employee-related expenses due to workforce reductions .
| Risk Type | Description | Impact |
|---|---|---|
| Competition | Intense competition in biotechnology | Pressure on market share and pricing |
| Regulatory | Complex regulatory environment | Delays in product approvals, increased costs |
| Operational | High R&D expenditures | Uncertainties in future revenue generation |
| Financial | Need for ongoing funding | Potential dilution of ownership, increased liabilities |
| Strategic | Dependence on collaborations | Risk of not achieving milestone payments |
In conclusion, understanding these risk factors is essential for investors considering the financial health and future prospects of the company.
Future Growth Prospects for Intellia Therapeutics, Inc. (NTLA)
Future Growth Prospects for Intellia Therapeutics, Inc.
Analysis of Key Growth Drivers
Intellia Therapeutics, Inc. is poised for growth driven by several factors:
- Product Innovations: The company is advancing its lead product candidates, NTLA-2001 and NTLA-2002, focusing on novel CRISPR/Cas9 technologies. NTLA-2001 has shown a 30% increase in external development expenses to $51.2 million for the nine months ended September 30, 2024, compared to $39.5 million in the same period in 2023 .
- Market Expansions: The firm is exploring new therapeutic areas and expanding its collaboration agreements, particularly with Regeneron, which has significantly contributed to its revenue.
- Acquisitions and Collaborations: Strategic partnerships, such as the collaboration with SparingVision, have provided a revenue stream of approximately $1.7 million in collaboration revenue for the nine months ended September 30, 2024 .
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, collaboration revenue increased by $6.8 million to $45.0 million from $38.2 million in the same period of 2023 . Analysts project continued revenue growth as product candidates advance through clinical trials and regulatory approvals.
Future earnings estimates suggest a gradual decrease in net losses, with a net loss of $390.1 million for the nine months ended September 30, 2024. This loss reflects ongoing investments in research and development, which are expected to yield future revenue as products move closer to commercialization.
Strategic Initiatives or Partnerships
Intellia is leveraging collaborations to enhance its growth potential. Key partnerships include:
- Collaboration with Regeneron, which has generated significant funding and resources for ongoing projects.
- License agreements with Kyverna and ONK, which could lead to milestone payments based on product development progress.
Competitive Advantages
Intellia's competitive position is strengthened by:
- Strong Intellectual Property Portfolio: The company is focused on protecting its innovations through extensive patent filings and collaborations.
- Access to Capital: As of September 30, 2024, Intellia had $944.7 million in cash, cash equivalents, and marketable securities, providing a solid financial foundation for ongoing operations.
- Experienced Management Team: The leadership team has a strong track record in biotechnology and regulatory affairs, positioning the company well for future growth.
| Metrics | 2024 (Nine Months Ended Sept 30) | 2023 (Nine Months Ended Sept 30) | Change |
|---|---|---|---|
| Collaboration Revenue | $45.0 million | $38.2 million | $6.8 million |
| Net Loss | $390.1 million | $349.0 million | $41.1 million |
| Research & Development Expenses | $349.4 million | $326.1 million | $23.3 million |
| Cash, Cash Equivalents & Marketable Securities | $944.7 million | N/A | N/A |
Intellia Therapeutics, Inc. (NTLA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Intellia Therapeutics, Inc. (NTLA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Intellia Therapeutics, Inc. (NTLA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Intellia Therapeutics, Inc. (NTLA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.